A role for hypertrophic astrocytes and astrocyte precursors in a case of rapidly progressive sclerosis

Multiple Sclerosis

Volumn 9, Issue 4, 2003, Pages 332-341

  Morcos, Yvette ^a   Lee, Sang Min ^a   Levin, Michael C ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Axon; Demyelination; Lesion; Myelin; Plaque; Remyelination

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; STEROID; VIMENTIN;

ADULT; ARTICLE; ASTROCYTE; CASE REPORT; DEMYELINATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHY; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYELINATED NERVE; NERVE FIBER; PARESTHESIA; PATHOGENESIS; PATHOLOGY; PHAGOCYTOSIS; REMYELINIZATION; STEM CELL; WHITE MATTER;

ASTROCYTES; BRAIN; DISEASE PROGRESSION; FATAL OUTCOME; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; NERVE REGENERATION; STEM CELLS; VIMENTIN;

EID: 0041622787     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms931oa     Document Type: Article

References (31)

1. Moore GRW. Neuropathology and pathophysiology of the multiple sclerosis lesion: In Paty DW, Ebers GC ed. Multiple Sclerosis. Philadelphia: FA Davis company, 1997: 257-327.
2. Lee SC, Moore GRW, Golenwsky G, Raine CS. Multiple sclerosis: A role for astroglia in active demyelination suggested by class I MHC expression and ultrastructural study. J Neuropathol Exp Neurol 1990; 49: 122-36.
3. Prineas JW, Kwon EE, Goldenberg PZ, Cho E-S. Sharer LR. Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions. Lab Invest 1990; 63: 624-36.
4. Wu E, Raine CS. Multiple sclerosis. Interactions between oligodendrocytes and hypertrophic astrocytes and their occurrence in other, nondemyelinating conditions. Lab Invest 1992; 67: 88-99.
5. Yamada T, Kawamata T, Walker DG, McGeer PL. Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 1992; 84: 157-62.
6. Dahl D, Rueger DC, Bignami A, Weber K, Osborn M. Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia. Eur J Cell Biol 1981; 24: 191-96.
7. Chu Y, Hughes S, Chan-Ling T. Differentiation and migration of astrocyte precursor cells (APC's) and astrocytes in human fetal retina: Relevance to optic nerve colomboma. FASEB J 2001; 15: 2013-15.
8. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull 1999; 49: 377-91.
9. Van Der Voorn P, Tekstra J, Beelen RHJ, Tensen CP, Van Der Valk P, De Groot CJA. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154: 45-51.
10. Ghatak NR. Occurrence of oligodendrocytes within astrocytes in demyelinating lesions. J Neuropathol Exp Neurol 1992; 51: 40-46.
11. Gutowski NJ, Newcombe J, Cuzner ML. Tenascin-R and C in multiple sclerosis: Relevance to extracellular matrix remodelling. Neuropathol App Neurobiol 1999; 25: 207-14
12. Grierson JP, Petroski RE, Ling DS, Geller HM. Astrocyte topography and tenascin cytotactin expression: Correlation with the ability to support neurite outgrowth. Brain Res Dev Brain Res 1990; 55: 11-19.
13. Faissner A, Kruse J. J1/Tenascin is a repulsive substrate for central nervous system neurons. Neuron 1990; 5: 627-37.
14. Groves AK, Entwistle A, Jat PS, Noble M. The characterization of astrocyte cell lines that display properties of glial scar tissue. Dev Biol 1993; 159: 87-104.
15. Meyer-Franke A, Shen S, Barres, BA. Astrocytes induce oligodendrocyte processes to align with and adhere to axons. Mol Cell Neurosci 1999; 14: 385-97.
16. Brück W, Schmied M, Suchanek G, Brück Y, Breitschopf H, Poser S et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65-73.
17. Eng LF, Yu ACH, Lee YL. Astrocytic response to injury. Prog Brain Res 1992; 94: 353-65.
18. Herx LM, Yong VW. Interleukin-1β is required for the early evolution of reactive astrogliosis following CNS lesion. J Neuropathol Exp Neurol 2001; 60: 961-71.
19. Peters A, Palay, SL and Webster, H def. The Fine Structure of the Nervous System. New York: Oxford University Press, 1991: 277.
20. Gisselsson D, Björk J, Höglund M, Mertens F, Dal Cin P, Åkerman M et al. Abnormal nuclear shape in solid tumors reflects mitotic instability. Am J Pathol 2001; 158: 199-206.
21. Mistelli T. Protein dynamics: Implications for nuclear architecture and gene expression. Science 2001; 291: 843-47.
22. Dundr M, Mistelli T. Functional architecture in the cell nucleus. Biochem J 2001; 356: 297-310.
23. Lamond AI, Earnshaw WC. Structure and function in the nucleus. Science 1998; 280: 547-53.
24. Locke M, Huie P. The nucleolus during epidermal development in an insect. Tissue Cell 1980; 12: 175-95.
25. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol 1994; 4: 229-37.
26. Qui J, Cai D, Filbin MT. Glial inhibition of nerve regeneration in the mature mammalian CNS. Glia 2000; 29: 166-74.
27. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000; 25: 1439-51.
28. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. New England J Med 1998; 338: 278-85.
29. Trapp BD, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
30. Oleszak EL, Zaczynska E, Bhattacharjee M, Butunoi C, Legido A, Katsetos CD. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diag Lab Immunol 1998; 5: 438-45.
31. Garthwaite G, Goodwin DA, Batchelor AM, Leeming K, Garthwaite J. Nitric oxide toxicity in CNS white matter: An in vitro study using rat optic nerve. Neuroscience 2002; 109: 145-55.